Login to Your Account



Phase III Trial Next

Following Phase IIb Miss, MediciNova Will Press Onward

By Catherine Shaffer
Staff Writer

Friday, May 25, 2012
A Phase IIb trial intended to show the benefit of MediciNova Inc.'s asthma candidate, MN-221, failed to meet its primary endpoint of improved forced expiratory volume in one second (FEV1) compared to placebo, sending the company's stock plummeting 43.3 percent Thursday.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription